Treatment options for obesity and potential therapies on the horizon.
نویسندگان
چکیده
Orlistat (Xenical, Alli) Orlistat (Xenical, Roche) is one of only two medications approved by the FDA for the treatment of obesity. A lipase inhibitor, it prevents the breakdown of dietary triglycerides to fatty acids and monoglycerides. The prescribed dose of 120 mg three times daily is taken with meals and prevents approximately 30% of ingested fat from being absorbed.6 According to a meta-analysis published in 2005, orlistat is associated with a mean weight loss of 2.6 kg at six months and a mean loss of 2.9 kg at 12 months, after the weight loss observed in the control group is subtracted.7 However, adverse effects (AEs), including flatulence, steatorrhea, increased stool frequency, fecal incontinence, and oily fecal discharge, limit the use of orlistat.5 This agent can also cause decreased absorption of the fat-soluble vitamins A, D, E, and K. Patients should thus be encouraged to take a supplement containing these vitamins two hours before each orlistat dose.6 Orlistat is also available over the counter as Alli (GlaxoSmithKline) at a 60-mg dose. Dr. Motycka is Assistant Dean and Director at the University of Florida’s College of Pharmacy, Jacksonville Campus, in Jacksonville, Fla. Dr. St. Onge is Assistant Dean and Director at the university’s College of Pharmacy, Orlando Campus, in Apoka, Fla. Dr. Miller is a member of the Pharmacotherapy Faculty at Florida Hospital, Family Health Center East, in Orlando.
منابع مشابه
Pnm-19: Ovarian Function and Obesity--Interrelationship,Impact on Women's ReproductiveLifespan and Treatment Options
Background: Insulin resistance (IR) is a consequence of obesity, and in women it is often inextricably linked with ovarian function leading to clinical reproductive manifestations such as early menarche onset, subfertility and polycystic ovary syndrome (PCOS). Materials and Methods: Likewise, the dramatic fall in oestrogen production after menopause may contribute to weight gain and changes in ...
متن کاملDevelopment of a Novel Anti-Obesity Compound with Inhibiting Properties on the Lipid Accumulation in 3T3-L1 Adipocytes
Background: Obesity as a developing global challenge can be characterized by increase in adipocyte number and size arising from adipogenesis. Control of adipogenesis, as a potential strategy, can prevent and manage obesity. So far, the effectiveness of herbal medicine and active ingredients therapies for obesity and metabolic syndrome treatment has been investigated. In this study, a novel comb...
متن کاملNew drug targets for the treatment of obesity.
There is a huge void in the current pharmacological treatment options for obesity. This gap is surprising given the high prevalence and associated costs of obesity. Many factors have prevented active drug development, including the poor safety and efficacy of earlier antiobesity drugs. However, there are now several compelling targets on the horizon. The new generation of antiobesity drugs offe...
متن کاملSignificant results of using laparoscopic adjustable gastric banding (LAGB) for the treatment of morbid obesity
Background: Morbid obesity contributes to many health risks including physical, emotional, and social problems. The increasing prevalence of obesity is a major public health concern since obesity is associated with several chronic diseases. Morbid obesity is one of the biggest independent risk factors for early mortality. Various options for the surgical treatment of morbid obesity have bee...
متن کاملCell based therapies in retinal diseases
Background Degenerative retinal diseases, including age related macular degeneration, glaucoma, and hereditary retinal dystrophies are major causes of blindness. The principal defect in these diseases is cell loss which is amenable to both cell based neuroprotective and neuroregenerative therapies. To briefly review the lines of research and potential candidates for cell based therapies among ...
متن کاملUpdate on medical treatment for Cushing’s disease
Cushing's disease (CD) is the most common cause of endogenous Cushing's syndrome (CS). The goal of treatment is to rapidly control cortisol excess and achieve long-term remission, to reverse the clinical features and reduce long-term complications associated with increased mortality. While pituitary surgery remains first line therapy, pituitary radiotherapy and bilateral adrenalectomy have trad...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 36 5 شماره
صفحات -
تاریخ انتشار 2011